Trial Profile
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2b Evaluation of the Onset and Duration of ADX-102 Ophthalmic Drops (0.5% and 0.1%) Compared to Vehicle of ADX-102 Ophthalmic Drops in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Reproxalap (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 21 Feb 2018 According to an Aldeyra Therapeutics media release, data will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
- 10 Oct 2017 According to an Aldeyra Therapeutics media release, data will be presented at the 2017 Research & Development Day.
- 10 Oct 2017 Results presented in an Aldeyra Therapeutics media release.